National Institute for Clinical Excellence (Hansard, 2 September 2003)

§ Mr. Baron
To ask the Secretary of State for Health if he will make a statement on the National Institute for Clinical Excellence's research into the use of riluzole for the treatment of motor neurone disease. [127028]

§ Dr. Ladyman
The National Institute for Clinical Excellence (NICE) issued guidance in January 2001 on the use of riluzole in the treatment of motor neurone disease. This guidance is due to be reviewed in 2004. Further details are available on NICE's website at www.nice.org.uk.

§ Mr. Baron
To ask the Secretary of State for Health if he will make a statement on the National Institute for Clinical Excellence's research into the diagnosis, management and treatment of Parkinson's disease in primary and secondary care. [127029]

§ Dr. Ladyman
The National Institute for Clinical Excellence (NICE) is currently preparing a guideline on the diagnosis, management and treatment of Parkinson's disease in primary and secondary care. The anticipated publication date for the guideline is July 2005. Further details are available from NICE's website at www.nice.org.uk

§ Mr. Baron
To ask the Secretary of State for Health if he will make a statement on the National Institute for Clinical Excellence's research into the use of(a) lamotrigine, (b) vigabatrin, (c) gabapentin, (d) oxcarbazepine, (e) topiramate and (f) tiagabine for the treatment of epilepsy in (i) children and (ii) adults. [127030]
12W

§ Dr. Ladyman
The National Institute for Clinical Excellence (NICE) is carrying out appraisals of these drugs and expects to publish its guidance in November 2003. Full details are on NICE's website at www. nice. org.uk.

§ Mr. Baron
To ask the Secretary of State for Health if he will make a statement on the National Institute for Clinical Excellence's research into the use of(a) memantine, (b) donepezil, (c) rivastigmine and (d) galantamine for the treatment of Alzheimer's disease. [127031]

§ Dr. Ladyman
The National Institute for Clinical Excellence (NICE) issued guidance on the use of donepezil, rivastigmine and galantamine for the treatment of mild to moderate Alzheimer's disease in January 2001. It will be conducting a review of its guidance and expects to publish revised guidance in May 2005. Memantine (for the treatment of moderate to severe Alzheimer's disease) is currently being appraised by NICE. The anticipated publication date of guidance is also May 2005. Full details are available on the website for NICE at www.nice.org.uk.